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Abstract
Background: Bone marrow-derived allogeneic mesenchymal stem cells (MSCs) from young healthy donors are
immunoprivileged and their clinical application for regenerative medicine is under evaluation. However, data from
preclinical and initial clinical trials indicate that allogeneic MSCs after transplantation provoke a host immune
response and are rejected. In the current study, we evaluated the effect of an increase in passage number in cell
culture on immunoprivilege of the MSCs. Since only limited numbers of MSCs can be sourced at a time from a
donor, it is imperative to expand them in culture to meet the necessary numbers required for cell therapy.
Presently, the most commonly used passages for transplantation include passages (P)3–7. Therefore, in this study
we included clinically relevant passages, i.e., P3, P5, and P7, for evaluation.
Methods: The immunoprivilege of MSCs was assessed with the mixed leukocyte reaction assay, where rat MSCs
were cocultured with peripheral blood leukocytes for 72 h. Leukocyte-mediated cytotoxicity, apoptosis (Bax/Bcl-xl
ratio), leukocyte proliferation, and alterations in cellular bioenergetics in MSCs were assessed after the coculture.
Furthermore, the expression of various oxidized phospholipids (oxidized phosphatidylcholine (ox-PC)) was analyzed
in MSCs using a lipidomic platform. To determine if the ox-PCs were acting in tandem with downstream intracellular
protein alterations, we performed proteome analysis using a liquid chromatography/mass spectrometry (LC/MS)
proteomic platform.
Results: Our data demonstrate that MSCs were immunoprivileged at all three passages since coculture with leukocytes
did not affect the survival of MSCs at P3, P5, and P7. We also found that, with an increase in the passage number of
MSCs, leukocytes did not cause any significant effect on cellular bioenergetics (basal respiration rate, spare respiratory
capacity, maximal respiration, and coupling efficiency). Interestingly, in our omics data, we detected alterations in some
of the ox-PCs and proteins in MSCs at different passages; however, these changes were not significant enough to
affect their immunoprivilege.
Conclusions: The outcome of this study demonstrates that an increase in passage number (from P3 to P7) in the cell
culture does not have any significant effect on the immunoprivilege of MSCs.
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Background
Bone marrow (BM)-derived mesenchymal stem cells
(MSCs) are attractive candidates for cell therapy since
these cells are immunoprivileged [1]. Therefore, allogen-
eic (unrelated donor) MSCs can suppress the host im-
mune system and survive after transplantation. In fact,
the outcome of numerous preclinical studies and initial
clinical trials have demonstrated that allogeneic BM-
MSCs after transplantation were able to initiate a re-
generative process [2]. However, long-term survival of
transplanted MSCs was not detected in the recipient
system. We recently reported in a rat model of myocar-
dial infarction that allogeneic MSCs after transplantation
into the infarcted heart lost their immunoprivilege and
were rejected by the host immune system [3]. The outcome
of our studies was confirmed by several other reports that
allogeneic MSCs after transplantation become immuno-
genic and are rejected by the recipient immune system [4].
Therefore, for a successful bench-to-bedside translation of
MSC-based regenerative therapies, it is imperative to
understand the mechanisms of immune switch in MSCs
from the immunoprivileged to immunogenic state.
To maintain uniformity in the quality of the cell product
for any allogeneic cell-based clinical trial, MSCs derived
from a single healthy donor are used for transplantation
in multiple recipients. Therefore, it is imperative to ex-
pand them in culture to facilitate generation of the re-
quired number of MSCs. The safety of various passages of
MSCs in the in-vitro studies has been amply demon-
strated. A recent study reported no changes in telomeric
ends for up to 25 passages [5]. However, subjecting MSCs
to passages in cell culture, even in the short term, has
been associated with physiological changes. Madeira et al.
reported major differences in the pathways pertaining to
culture-induced senescence [6]. There are numerous fac-
tors that may influence the overall optimum physiology of
the cells, and these may be affected by the passaging of
MSCs. The cell surface lipidome analysis of MSCs is
garnering attention of late. The passaging of MSCs was
found to alter levels of cell surface lipids and immune-
modulation [7]. The oxidized phospholipids (oxidized
phosphatidylcholine (ox-PC)), in particular, are known to
affect the immunological behavior of cells [8]. Further-
more, cellular bioenergetics including cellular respiration
and metabolic pathways are instrumental to stem cell re-
newal, maintenance, and general cell health [9]. Altered
metabolic pathways lead to a difference in the functional
capabilities of stem cells [10]. It is reported that, with an
increase in passage number in the culture, cellular bio-
energetics and growth rate are affected [11, 12].
Therefore, in this study, we have attempted to investi-
gate the effect of an increase in passage number in cell
culture on the immunological behavior of MSCs. The
most commonly used passages for cell therapy in
ongoing clinical studies include passage (P)3–7. In this
study, we included the clinically relevant passages, i.e.,
P3, P5, and P7, for evaluation. We have employed func-
tional evaluation as well as whole cell high-throughput
assessment. We have chosen parameters including cell
surface ox-PCs, cellular bioenergetics, global proteomic
assessment, and general immune as well as cell survival
pathways for our investigations. These characteristics
have hitherto not been studied in detail. With MSCs
poised at the cusp of clinical application, it is becoming
increasingly apparent that our knowledge is very limited
in various attempts to transfer understanding from the
in-vitro setting into in-vivo applications.
Methods
Experimental animals
Unrelated male Sprague-Dawley (SD) rats (200–250 g)
were used for the isolation of bone marrow MSCs and
for the isolation of peripheral blood leukocytes. The
study protocol was approved by the Animal Care
Committee of the University of Manitoba and con-
formed to the ‘Guide for the Care and Use of Laboratory
Animals’ published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1985).
MSC isolation and characterization
Bone marrow cells were flushed from the cavities of
femur and tibias of SD rats. After the connective tissue
was removed from around the bones, both ends were
cut. The bone marrow plugs were flushed with Dulbec-
co’s modified Eagle’s medium supplemented with 15%
fetal bovine serum (FBS), 100 units/ml penicillin G, and
0.1 mg/ml streptomycin. Cells were plated and cultured
in the same medium followed by a media change and
the removal of nonadherent hematopoietic cells the next
day. The medium was replaced every 3 days, and the
cells were subcultured when confluency exceeded 90%.
MSCs from passages 3, 5, and 7 were used for the
studies described herein.
MSCs were characterized by flow cytometry as de-
scribed previously [3]; the cell population which was
identified as CD90.1+, CD29+, CD45−, and CD34− was
used for further experiments. To further characterize the
cells, MSCs were analyzed for their ability to differentiate
into osteogenic, adipogenic, and chondrogenic lineages
using a kit (R&D systems, catalogue number SC020). The
cells were induced to differentiate and stained using
reagents and primary antibodies provided in the kit
(osteocalcin for osteogenic differentiation; FABP4 for
adipogenic differentiation; aggrecan for chondrogenic
differentiation). The secondary antibodies used (AF488 for
osteocytes; AF647 for adipocytes and chondrocytes) were
purchased separately. The nuclei were stained with DAPI.
The images were captured using a Cytation5 at 20×
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magnification. Additionally, differentiated MSCS were
also stained using Alizarin Red (osteogenic) and Oil
Red-O stain (adipogenic).
MSC population doubling
The population doubling time of MSCs at different pas-
sages was calculated using a trypan blue cell viability
assay. The cells were plated at 100,000 cells/well in six-
well dishes. After 96 h of culture, the MSCs were de-
tached using trypsin EDTA followed by staining with
trypan blue and counting of the live cell number using
an automated cell counter (BioRad). The doubling time
was calculated as follows:
Doubling time ¼ time of culture
 log 2ð Þ= log final cell numberð Þ
– log initial cell numberð Þ
Mixed leukocyte-mediated cytotoxicity
Leukocytes were isolated from rat spleen using
HISTOPAQUE 1083 (Sigma-Aldrich) and cocultured
with allogeneic MSCs at different passages (3, 5, and
7) at a ratio of 10:1 (leukocytes:MSCs). After 72 h of
coculture, leukocyte-mediated cytotoxicity in MSCs
was assessed by a Live/Dead viability/cytotoxicity
assay kit (Thermo Fisher Scientific, L3224).
Assessment of apoptosis
Apoptosis in MSCs at different passages (P3, P5, and P7)
was assessed after 72 h of coculture with mixed leuko-
cytes by measuring Bax and Bcl-xl levels using Western
blot. Briefly, total protein levels were measured by Brad-
ford protein assay, and 25 μg of protein was used in each
group for SDS-PAGE electrophoresis. After separation
with electrophoresis, proteins were transferred to PVDF
membranes and probed with primary antibodies for Bax
and Bcl-xl (Santa Cruz Biotechnologies Inc., CA, USA)
and secondary antibodies (Biorad Inc.). The membranes
were developed using x-ray film, and bands were quanti-
fied using Quantity One software for densitometry.
Leukocyte proliferation
The effect of MSCs on the proliferation of leukocytes
was analyzed using an MLR assay. Leukocytes were
cocultured with allogeneic MSCs at different passages
(P3, P5, and P7) for 72 h at a ratio of 1:10 (MSCs:leuko-
cytes). The leukocyte proliferation was measured by flow
cytometry (BD Accuri). Briefly, after coculture, the leu-
kocytes in the supernatant were collected and spun at
1000 rpm for 5 min. The pellet was washed three times
using 1× phosphate-buffered saline (PBS), and sus-
pended in 100 μl cold PBS. The cells were then fixed
using 5 ml ice-cold 70% ethanol followed by RNase
(20 μg/ml) treatment for 30 min. The cells were then
stained with propidium iodide (PI; 5 μg/ml) for 5 min at
room temperature and analyzed using flow cytometry.
To measure leukocyte proliferation, a cell cycle analysis
was performed by counting the number of cells entering
the S phase (proliferating phase) and the G2/M phase
from the G0/G1 phase (resting cells) of the cell cycle.
Assessment of the secretion profile of leukocytes
The leukocytes were cocultured with MSCs at different
passages for 72 h at a ratio of 1:10 (MSCs:leukocytes).
The cytokine secretion profile of leukocytes was ana-
lyzed using a multianalyte rat cytokine ELISArray kit
(Qiagen; MER 336161) following instructions from the
manufacturer. We analyzed the levels of 12 different cy-
tokines including interleukin (IL)-1α, IL-1β, IL-2, IL-4,
IL-6, IL-10, IL-12, IL-13, interferon (IFN)-δ, tumor ne-
crosis factor (TNF)-α, granulocyte-macrophage colony-
stimulating factor (GM-CSF), and RANTES. The plate
was read at 450 and 570 nm using a Cytation5 analyzer
(BioTek Inc.) in plate reader mode.
Measurement of cellular bioenergetics
The cellular bioenergetics were determined using the
extracellular flux (XF24) analyzer (Seahorse Bioscience).
MSCs (4 × 104 cells/well) and leukocytes were cocultured
at a ratio of 1:10 (MSCs:leukocytes) in XF24 plates for
72 h. The mean basal respiration was determined by
recording oxygen consumption rate (OCR) measurements
before adding inhibitors or activators. ATP-linked OCR
and proton leak were determined by injecting oligomycin
(1 μM). The maximal respiration rate was determined
after adding FCCP (an uncoupler of the electron transport
chain) at a concentration of 1 μM. The difference between
the basal rate and this FCCP-stimulated rate is the reserve
capacity of the mitochondria, which is a measure of the
maximal potential respiratory capacity the cell can utilize
under conditions of stress and/or increased energetic de-
mands. To completely inhibit mitochondrial electron
transport, antimycin A (1 μM) and rotenone (1 μM) were
used. The OCR determined after rotenone and antimycin
A injection is attributable to nonmitochondrial oxygen
consumption. Mitochondrial basal respiration, proton
leak, and the maximal respiration were calculated after
corrections were performed for the nonmitochondrial
OCR for each assay. Under these conditions, viability was
over 90% for all cell types and remained so over the time
course of the assay. At the end of the assay period, trypsi-
nized cells were collected, and values were normalized to
the total cell number in each well [13].
Oxylipidomic analysis
Cell surface oxidized phosphatidylcholine (ox-PCs)
levels were measured in MSCs at different passages
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(P3, P5, and P7) by liquid chromatography/mass spec-
trometry (LC/MS) analysis. Total cellular lipids were ex-
tracted from cell pellets using a protocol adapted from
Folch et al. [14]. Oxylipidomic analysis was performed
with reverse-phase high-performance liquid chromatog-
raphy (HPLC) using an Ascentis Express C18 column
(Supelco Analytical, Bellefonte, PA, USA). Data were col-
lected using analyst 1.6 software (Applied Biosystems,
Canada) and quantified using MultiQuant 2.1 (Absciex,
Ontario, Canada). The mass spectrometry data were log
transformed and autoscaled (mean-centered and divided
by standard deviation of each variable) before applying
statistical analysis. To determine the changes in ox-PCs
that were statistically significant between different pas-
sages P3, P5, and P7, we performed a one-way analysis of
variance (ANOVA) with a p value cut-off of 0.05, followed
by Tukey’s Honestly Significant Difference (Tukey’s HSD).
E06 antibody treatment
E06 is a blocking antibody that specifically inhibits oxi-
dized phosphatidylcholines in cells. To assess the in-
volvement of ox-PCs in regulating leukocyte-mediated
cytotoxicity, apoptosis, and cellular bioenergetics in
MSCs, we cocultured MSCs and leukocytes with or
without E06 antibody (1 ng/ml) (MSC + L + Ab) for 72 h
and measured the abovementioned parameters.
Proteomic analysis
Sample preparation for mass spectrometry
Whole cell proteomic analysis was performed in MSCs
at different passages (P3, P5, and P7) by the LC/MS
proteomic platform. MSCs were cultured at different
passages, and cell pellets were collected and washed in
ice-cold PBS (pH 7.2) followed by treatment with urea
lysis buffer (8 M urea in 0.1 M Tris-HCl, pH 8.5). Pro-
tein estimation was performed by Qubit fluorescence
assay (Invitrogen). A total of 50 μg protein was digested
using the FASP procedure as described previously [15].
Liquid chromatography tandem mass spectrometric ana-
lysis of tryptic peptides (500 ng) was carried out using a
Proxeon nano spray ESI source (Thermo Fisher, Hemel,
UK) and analyzed using Orbitrap Velos Pro FTMS
(Thermo Finnigan, Bremen, Germany) [16].
Proteomic data analysis by MaxQuant
Peptides and proteins were identified by Andromeda via
an automated database search of all tandem mass spectra
against a curated target/decoy database (using forward
and reverse versions of the Rattus norvegicus [Taxonomy
ID 10116]) and Uniprot protein sequence database
(http://www.uniprot.org; release October 2015) containing
all rat protein entries from Swiss-Prot and TrEMBL.
Cysteine carbamidomethylation was searched as a fixed
modification, whereas N-acetyl protein, deamidated NQ,
and oxidized methionine were searched as a variable
modification. The resulting Andromeda peak list-output
files were further processed using MaxQuant software.
The downstream bioinformatics data analysis was carried
out using the Perseus software suite (1.5.0.15) and the
Ingenuity Pathway Analysis software tool (Ingenuity
Systems, Qiagen, Redwood City).
Statistical analysis
Experimental values are expressed as mean ± SD. The
comparison of mean values between various groups was
performed by one-way ANOVA followed by multiple
comparisons by Tukey test using the software GraphPad
Prism. A p value < 0.05 was considered to be significant.
Results
Differentiation of MSCs
To characterize MSCs, cells were induced to differen-
tiate toward the adipogenic, osteogenic, and chondro-
genic lineages. Our data demonstrate that MSCs have
the ability to differentiate toward these three lineages
(Additional file 1: Figure S1).
Population doubling of MSCs at different passages
To investigate the effect of an increase in passage num-
ber on population doubling time of MSCs, a cell viability
assay was performed; our data demonstrate that there
was no significant difference in the population doubling
time of MSCs in the culture at P3, 5, or 7 (Fig. 1a).
MSCs show no significant changes in immunological
behavior with an increase in passage number
Bone marrow-derived MSCs are reported to be immu-
noprivileged and thus are able to escape the host im-
mune system after transplantation. To understand the
effect of an increase in passage number on the immuno-
privilege of MSCs, cells at P3, P5, and P7 were cocul-
tured with mixed leukocytes. The leukocyte-mediated
cytotoxicity was measured in MSCs. Our results demon-
strate that MSCs were immunoprivileged at all three
passages (P3, P5, and P7) since we found more than 80%
live cells even after 72 h of coculture with leukocytes
(Fig. 1b). Interestingly, there was no significant difference
detected in the number of live/dead MSCs at different
passages after the coculture (Fig. 1b). We also assessed
leukocyte-mediated apoptosis of MSCs and found no sig-
nificant difference in the ratio of the antiapoptotic protein
Bcl-xl and the proapoptotic protein Bax at P3, P5, and P7
after coculture with leukocytes (Fig. 1c).
Mesenchymal stem cells have the ability to suppress
immune cell proliferation and promote immune toler-
ance. We analyzed the effect of an increase in passage
number of MSCs on their ability to suppress leukocyte
proliferation and found that there were no significant
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differences in the level of suppression of leukocyte pro-
liferation by MSCs at different passages (Fig. 2a). The
data are represented as different stages of the cell
cycle including G0/G1 phase, S phase, and G2/M
phase. G1/G0 phase represents the stage where the
cells prepare for the next division cycle by synthesizing
proteins and RNA required for the division and multipli-
cation. In S phase, the DNA synthesis occurs allowing the
cells in G2/M phase to have double DNA which becomes
divided equally in the cells once they undergo mitotic cell
division. There were no significant differences observed at
any stage among the different passages, indicating that the
MSCs at P3, 5, and 7 affect leukocyte proliferation at the
same rate.
To further assess the effect of MSCs at different pas-
sages on the immunomodulatory effects of leukocytes,
we analyzed the levels of several proinflammatory cytokines
including IL-1α, IL-1β, IL-2, IL-6, IL-12, IFN-γ, TNF-α,
GM-CSF, and RANTES, and the anti-inflammatory cyto-
kines IL-4, IL-10, and IL-13 in leukocytes after coculture
with MSCs. Our data demonstrate that there was no signifi-
cant change in the levels of these soluble factors in leuko-
cytes after coculture with MSCs at different passages
(Fig. 2b, c). These results suggest that an increase in
a b
c
Fig. 1 Assessment of doubling time and immunoprivilege of MSCs. a Population doubling of MSCs at different passages was determined using
trypan blue cell viability assay. The cells were plated in equal numbers followed by calculating the live cell number after 96 h of culture. There
was no significant difference found in population doubling time of cells at different passages. b, c MSCs were cocultured with leukocytes (with or
without E06 blocking antibody) for 72 h at a ratio of 1:10 (MSCs:leukocytes). b Leukocyte-mediated cytotoxicity in MSCs at different passages was
determined by cytotoxicity assay kit using flow cytometry. There was no significant difference found in the level of cytotoxicity at different passages in the
presence of leukocytes alone or in the presence of leukocytes and E06 antibody. c Western blot analysis was performed to determine the levels of the pro-
and antiapoptotic proteins Bax and Bcl-xL. There was no significant difference observed in the Bax/Bcl-xl ratio in MSCs at different passages in the presence
of leukocytes alone or in the presence of leukocytes and E06 antibody. Data are represented as mean ± SD (n= 3–6). ML, MSCs + leukocytes; MLA,
MSCs + leukocytes + E06 antibody; MSC, mesenchymal stem cells
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the passage number from P3 to P7 does not affect
immunoprivilege and immune tolerance of MSCs.
Effect of an increase in passage number on cellular
bioenergetics
It is reported that intracellular energy metabolism has a
primary influence on the presence or absence of T-cell
activation signals. Therefore, cellular bioenergetics are a
key factor for determining the response of transplanted
cells toward the host immune system. We assessed the
effect of an increase in passage number on the intracellu-
lar energy metabolism using a SeaHorse Bioscience XF24
analyzer. We found no significant difference in basal res-
piration rate and spare respiratory capacity in MSCs at P3,
P5, and P7 before and after coculture with leukocytes
(Fig. 3a, b). We also measured the maximal respiration
along with coupling efficiency of MSCs in the presence
as well as absence of leukocytes. Our data indicate that
there was no significant difference observed in any of
these parameters at different passages (Fig. 3c, d).
Oxidized phosphatidylcholine (ox-PCs) levels change in
MSCs without affecting immunoprivilege
The cellular ox-PCs have been recognized as important
mediators of immune signaling. To assess changes in the
total cell oxylipidome at different passages and their ef-
fect on immunoprivilege of MSCs, the cells at P3, P5,
and P7 were subjected to LC/MS analysis. Our data
demonstrate that, overall, there were no significant fea-
tures identified between the passages (Fig. 4a, b). How-
ever, some of the ox-PCs which are already reported (in
other cell types) to play a significant role in immune cell
suppression and were found to be altered with an in-
crease in passage number in the current study are
SOVPC, KDdiA SPC, PAPC-OOH, SAPC-keto, and
SECPC (Fig. 4b).
To explore whether changes in the levels of ox-PCs have
any effect on the immunological behavior of MSCs, we
added E06 antibody in the coculture experiments and
assessed leukocyte-mediated cytotoxicity and apoptosis in
MSCs. The E06 antibody is responsible for blocking cell
surface ox-PCs. Our data demonstrate that the presence
of the antibody did not have any significant effect on the
number of live/dead MSCs and apoptosis after coculture
with leukocytes (Fig. 1b, c). Furthermore, the presence of
E06 antibody did not cause any difference in cellular bio-
energetics. We did not see any significant changes in the
basal respiration rate, spare respiratory capacity, coupling
efficiency, or maximal respiration rate before and after the
addition of the E06 blocking antibody (Fig. 3a–d). Hence,
a b
c
Fig. 2 Effect of MSCs on leukocyte proliferation and the secretion profile of leukocytes. Leukocytes were cocultured with MSCs at passages 3, 5,
and 7 at a ratio of 1:10 (MSCs:leukocytes) for 72 h. a Leukocyte proliferation was measured by flow cytometry. The data are represented as different
stages of the cell cycle: G0/G1 phase, S phase, and M phase. The extent of leukocyte proliferation by MSCs did not change with an increase in passage
number since there was no significant difference found in the number of leukocytes at different stages of the cell cycle among different passages. The
effect of an increase in passage number of MSCs on the secretion of b anti-inflammatory and c proinflammatory cytokines by leukocytes was analyzed
using ELISA array. The results indicate that MSCs at different passages had no significant effect on the secretion profile of leukocytes. Data are represented
as mean ± SD (n= 3–4). GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LC, leukocytes alone; ML3, leukocytes
cocultured with MSCs at P3; ML5, leukocytes cocultured with MSCs at P5; ML7, leukocytes cocultured with MSCs at P7; TNF, tumor necrosis factor
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alterations in individual cell surface ox-PCs from P3 to P7
do not affect the immunological properties or cellular bio-
energetics of MSCs.
The stem cell proteome is largely unchanged over
different passages
We performed whole-cell proteomic analysis at different
passages using LC/MS to study changes in the levels of
intracellular proteins related to cellular senescence, im-
munogenicity, and bioenergetics. In total, over 800 pro-
teins were screened (Fig. 5a). Our proteomic data
recorded some changes in the levels of proteins associ-
ated with cellular senescence and aging (Fig. 5b) and im-
munological synapse (Fig. 5c). Furthermore, some of the
proteins that have been reported to play a role in cellular
respiration pathways including glycolysis and oxidative
phosphorylation as well as tricarboxylic acid (TCA) cycle
showed changes with the increase in passage number
(Fig. 5d–f ). The proteomic analyses for mitochondrial
pathways also indicated changes in some proteins in P7
versus P3 (Additional file 2: Figure S2). However, overall,
the extent of change recorded in intracellular proteins
was not significantly different among P3 and P7, and the
changes recorded were not able to affect immunological
behavior of MSCs.
Discussion
In various animal models of degenerative diseases, trans-
plantation of bone marrow-derived allogeneic MSCs has
triggered regenerative processes. Based on the encour-
aging outcome of animal-based studies, several clinical
trials have tested the efficacy of allogeneic MSCs. Al-
though the outcome of allogeneic cell-based clinical tri-
als has been encouraging, it is not as effective as the
outcome of preclinical studies. Some of the recent stud-
ies reported that allogeneic MSCs after transplantation
were immunogenic and were rejected by the host im-
mune system. Therefore, understanding the mechanisms
of the switch in the immunological behavior of MSCs
from immunoprivileged to the immunogenic state would
help in preserving the benefits of allogeneic MSCs. The
current study is the first to evaluate the possible role of
cellular bioenergetics and cell surface ox-PCs in combin-
ation with intracellular proteomic analysis in regulating
the immunoprivilege of MSCs over different passages.
The notion that an increase in passage number in cell
culture may affect cellular physiology, morphology, and
particularly cell surface molecules is being actively de-
bated. It has been suggested that senescence of MSCs
starts as soon as their culturing is initiated. Furthermore,
the cells start losing the ability to differentiate, doubling
capacity, and telomere length as the passage number in-
creases in cell culture [17]. The outcomes of the major-
ity of MSC-based animal studies and clinical trials have
suggested that allogeneic MSCs after transplantation
were immunoprivileged and there was no immune re-
sponse detected in the recipient system against trans-





Fig. 3 Measurement of cellular bioenergetics using XF24 Seahorse
analyzer. Mesenchymal stem cells (MSCs) at passages 3, 5, and 7
were cocultured with leukocytes (with or without E06 blocking
antibody) at a ratio of 1:10 (MSCs:leukocytes) for 72 h. a Basal
respiration rate, b spare respiratory capacity, c coupling efficiency,
and d maximal respiration rate were measured in MSCs. There were
no significant changes observed in these parameters in MSCs with
the increase in passage number, in the presence of leukocytes, and
in the presence of E06 antibody. The values are normalized to cell
number in each well. Data are represented as mean ± SD (n = 4–6).
MSC + L, MSCs + leukocytes; MSC + L + Ab, MSCs + leukocytes +
E06 antibody
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revealed that antidonor alloantibodies were detected
against transplanted MSCs [3, 20] and cells were rejected
by the recipient immune system. One of the important
variables in these studies was that cells employed for these
studies were from different passages. Therefore, in this
study we investigated the effect of an increase in passage
number in cell culture on the immunological behavior
of MSCs. The most commonly used passages for cell
therapy in concluded or ongoing studies include pas-
sages 3–7. Therefore, in the current study, we included
P3, P5, and P7 for evaluation. Our investigations were
focused on hitherto untested parameters of cell surface
ox-PCs, cellular bioenergetics, global, and proteomic
assessment.
Previous studies have reported an association of
cellular senescence with alterations in the immuno-
logical behavior of MSCs [21–23]. Senescent cells are re-
ported to attract immune cells; for instance, fibroblasts
undergoing senescence secrete various cytokines as well
as chemokines which lead to activation of lymphocytes
and macrophages [23]. At the organ level, it is reported
that kidneys from old donors are more prone to rejec-
tion by the host immune system compared with those
from young donors [24]. Additionally, in the case of
bone marrow-derived MSCs, senescence is associated
with a reduced differentiation and proliferation potential
[25]. Furthermore, radiation-induced senescence in MSCs
is associated with abrogation of the immunomodulatory
properties and impaired therapeutic potential in vivo in a
mouse model of sepsis [26]. However, the effect of an in-
crease in passage number on immunoprivilege of MSCs
has not been investigated thoroughly. Therefore, to inves-
tigate this, in the current study we analyzed cellular
changes in immunogenicity at different passages. We
found that an increase in passage number from P3 to P7
did not have any significant effect on immunoprivilege of
Fig. 4 Oxylipidome profile of MSCs by LC/MS was carried out at passages 3, 5, and 7. a One-way analysis of variance (ANOVA) plot with a p value
threshold of 0.05. b Clustered heatmap (distance measure using euclidean, and clustering algorithm using ward) showing the intensity of 55
ox-PC compounds. Each row represents data for a specific ox-PC compound and each column represents an individual passage (P3, P5, and P7).
All values are log-normalized values of detected abundance for each ox-PC compound. The colors changing from high (red) to low (blue) correspond
to the different intensity level of ox-PCs (n = 3)
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MSCs since leukocyte-mediated cytotoxicity and cell
death in MSCs did not change between the different pas-
sages. Furthermore, there was no significant difference ob-
served in the MSC-mediated suppression of leukocyte
proliferation with different passages of MSCs.
Several studies in the literature have reported the role
of the cellular bioenergetics profile in the regulation of
immune response. The mode of intracellular respiration
plays a key role in influencing the presence or absence
of T-cell activation signals and thus regulating immuno-
privilege of a cell [27, 28]. The choice of fuel (glucose or
fatty acids) used for mitochondrial metabolism regu-
lates the interaction of the cell with the immune system
[29, 30]. In dendritic cells, there is a switch in the mode
of metabolism from oxidative phosphorylation to gly-
colysis that triggers their activation [31]. In another
study, the effect of blocking mitochondrial respiration
was reported to reduce the binding of TNF-α to the
cells, indicating that mitochondrial respiration might be
an important mediator of the immune responses con-
trolled by TNF-α [32]. To assess the effects of an in-
crease in passage number on the cellular respiratory
profile in MSCs and its association with the immuno-
privilege of MSCs, we performed Seahorse XF24 ana-
lysis at different passages. Our data demonstrate that
within clinically relevant passages an increase in pas-
sage number in cell culture from P3 to P7 did not affect
basal respiration rate, spare respiratory capacity, max-
imal respiration, or coupling efficiency in MSCs before
and after coculture with leukocytes.
Another major modulator for the immunogenicity of
cells is the expression of cell surface ox-PCs. Several
studies have described the role of oxidized phosphatidyl-
cholines in modulating the immunological behavior of
immune cells. Oxidation of phospholipids under various





Fig. 5 Whole-cell proteome analysis of MSCs at passages 3 and 7 was performed using the LC/MS proteomic platform to determine the changes
in different proteins with the increase in passage number. a Volcano plot of all the proteins shows no significant changes in all but 18 (shown in
red color) proteins (p < 0.05). b–f The values of proteins involved in different pathways including cellular senescence (b), immunological synapse
(c), glycolysis (d), tricarboxylic acid (TCA) cycle (e), and oxidative phosphorylation (f). Log2 fold change ratios of protein values at P7 versus P3
were calculated. The protein values between −1 and + 1 were considered to be normal and not changing significantly. Values higher than +1
indicate significant upregulation (at P7 compared to P3) of the protein and values lower than −1 indicate significant downregulation of the
protein levels (n = 3)
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leads to the generation of proinflammatory damage-
associated molecular products (DAMPs) that leads to rec-
ognition of the cells expressing these epitopes by the innate
immune system [33]. During atherosclerosis, ox-PCs in-
cluding phosphatidylcholines served as signals for uptake of
the cells expressing the phospholipids [34]. However, antag-
onistic to their role in immune cell activation, oxidized
phospholipids are also reported to be involved in prevent-
ing the activation of T lymphocytes [35]. Adding to their
immunosuppressive role, oxidized phospholipids are also
known to prevent the activation of dendritic cells by Toll-
like receptor (TLR)3- and TLR4-mediated pathways [36].
These lipids can be both the mediators and the result of
cellular apoptosis in different cell types [37]. In various
models, the cells expressing the oxidized phospholipids are
recognized by macrophages for apoptosis [38]. Interestingly,
the macrophages might themselves undergo apoptosis due
to activation of the TLR pathway by oxidized phospholipids
[39]. Therefore, ox-PCs play an important role in mediating
the cellular response to the immune system. To assess the
effect of oxidized phospholipids on the immunoprivilege of
MSCs in different passages, we performed LC/MS lipido-
mic analysis. Our data revealed that some of the ox-PCs
were changing with the increase in passage number. How-
ever, alterations in ox-PCs did not affect immunoprivilege
of MSCs. To determine if the ox-PCs were acting in tan-
dem with downstream intracellular protein alterations, we
performed proteome analysis using the LC/MS proteomic
platform to screen more than 800 proteins. The overall
trend recorded in intracellular proteins did not change in
MSCs with an increase in passage number. However, we
found changes in some proteins involved in cellular senes-
cence and metabolism, but these changes were not able to
affect the immunological behavior of MSCs.
Conclusion
Our study suggests that an increase in passage number
from P3 to P7 does not affect immunoprivilege of MSCs.
However, more studies are needed to delineate the
mechanisms of switch in the immunological behavior of
MSCs after transplantation.
Additional files
Additional file 1: Figure S1. Differentiation of MSCs into osteocytes,
adipocytes, and chondrocytes. MSCs were induced to differentiate
toward osteocytes (a), adipocytes (b), and chondrocytes (c). MSCs
(undifferentiated cells, control group) and differentiated MSCs (D-MSC)
were stained for osteocalcin and Alizarin Red (osteocyte lineage), FABP4
and Oil Red-O stain (adipocyte lineage), and aggrecan (chondrocyte
lineage). The images were taken using Cytation5 (BioTek Instruments)
(20× magnification). (n = 6) (PPTX 2648 kb)
Additional file 2: Figure S2. Heat map showing the highly upregulated
or downregulated proteins that are known to be associated with
mitochondrial respiration and immune pathways at P3 versus P7.
(PPTX 5354 kb)
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